Updated Results of a Phase II Trial of Ibrutinib and Rituximab for High-Risk CLL


Updated Results of a Phase II Trial of Ibrutinib and Rituximab for High-Risk CLL
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (2/13/14)
Burger JA et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): New, updated results of a Phase II trial in 40 patients. Proc ASH 2013;Abstract 675.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at the UW Carbone Cancer Center in Madison, Wisconsin.